Literature DB >> 10833331

Polymorphisms in the CBS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid.

W D Kruger1, A A Evans, L Wang, M R Malinow, P B Duell, P H Anderson, P C Block, D L Hess, E E Graf, B Upson.   

Abstract

Elevated total plasma homocysteine (tHcy) is an established risk factor for the development of vascular disease and neural tube defects. Total homocysteine levels can be lowered by folic acid supplements but individual response is highly variable. In this case-control study, involving 142 coronary artery disease (CAD) patients and 102 controls, we have typed six genetic polymorphisms in three homocysteine metabolizing genes and examined their relationship to the incidence of CAD, tHcy levels, and lowering of tHcy levels in response to folic acid supplementation. We found that two single nucleotide polymorphisms in the cystathionine beta synthase (CBS) gene, 699C --> T and 1080T --> C, are associated with decreased risk of CAD and increased responsiveness to the tHcy lowering effects of folic acid. Individuals homozygous for 699T were significantly underrepresented in CAD patients as compared to controls (4.9% vs 17.3%, P = 0.0015), as were individuals homozygous for the 1080C (29.6% vs 44.2%, P = 0.018). Additionally, 699T and 1080C homozygous individuals were the most responsive to folate supplementation. 699T homozygotes lowered tHcy levels 13.6% on average, compared to 4.8% lowering in 699C homozygotes (P = 0.009), while 1080C homozygotes lowered 12.9% compared to just 2.7% for 1080T homozygotes (P = 0.005). The two polymorphisms in CBS are third codon changes and would not be predicted to affect the underlying protein. However, there is strong linkage disequilibrium between these two positions, suggesting that they may also be linked to other as yet unidentified polymorphisms within the CBS gene. These observations suggest that specific CBS alleles are a risk factor for the development of vascular disease and that genetic information could be predictive of individual response to folic acid supplementation. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10833331     DOI: 10.1006/mgme.2000.2993

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

1.  Neural tube defects and maternal biomarkers of folate, homocysteine, and glutathione metabolism.

Authors:  Weizhi Zhao; Bridget S Mosley; Mario A Cleves; Stepan Melnyk; S Jill James; Charlotte A Hobbs
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2006-04

Review 2.  Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview.

Authors:  R Castro; I Rivera; H J Blom; C Jakobs; I Tavares de Almeida
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

3.  Short-term folic acid supplementation induces variable and paradoxical changes in plasma homocyst(e)ine concentrations.

Authors:  M R Malinow; P B Duell; M A Williams; W D Kruger; A A Evans; P H Anderson; P C Block; D L Hess; B M Upson; E E Graf; A Irvin-Jones; L Wang
Journal:  Lipids       Date:  2001       Impact factor: 1.880

4.  Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation.

Authors:  Jane C Figueiredo; A Joan Levine; Maria V Grau; Oivind Midttun; Per M Ueland; Dennis J Ahnen; Elizabeth L Barry; Shirley Tsang; David Munroe; Iqbal Ali; Robert W Haile; Robert S Sandler; John A Baron
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

5.  Management and Prevention of Stroke Associated with Elevated Homocysteine.

Authors:  Peter J. Kelly; Karen L. Furie
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-10

Review 6.  Hyperhomocysteinemia is an emerging comorbidity in ischemic stroke.

Authors:  Ranjana Poddar
Journal:  Exp Neurol       Date:  2020-12-03       Impact factor: 5.330

Review 7.  Hyperhomocysteinemia in renal diseases.

Authors:  Dumitru Ferechide; Daniela Radulescu
Journal:  J Med Life       Date:  2009 Jan-Mar
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.